Pharmacy benefit manager Prime Therapeutics LLC has signed a value-based contract with Janssen for Stelara, a prescription drug used to treat moderate or severe plaque psoriasis.
According to a press release, Prime Therapeutics will analyze claims data for individuals using Stelara to gauge how long they use the treatment. Determining that time period is key because “it’s only when patients continue to take their medications for the prescribed amount of time that they obtain the intended benefit from the therapy.”
“Our clients invest in specialty medications and if members don’t continue to take them, no one realizes the value of the investment,” Prime Therapeutics Vice President of Pharmaceutical Trade Relations Susan Scheid said in a statement. “Prime (Therapeutics) uses insights from its value-based contracts to build clinical programs to improve member health outcomes.”
About Prime Therapeutics
Prime Therapeutics helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and offers clinical services for people with complex medical conditions. Prime serves more than 27 million people. It is collectively owned by 18 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. For more information, visit www.primetherapeutics.com or follow @Prime_PBM on Twitter.
To read the full press release on PRNewswire, click here.